Abstracts tagged "Cardiovascular disease"

Abstract Number: 2401 • 2017 ACR/ARHP Annual Meeting
Rheumatoid Arthritis with Kidney Dysfunction Contributes to Higher Risk of Cardiovascular Disease Development
Suad Hannawi¹ and Issa Al Salmi², ¹Rheumatology, Asst.Prof, Dubai, United Arab Emirates, ²Prof, Muscat, Oman
Background/Purpose: Reduced kidney function render patients with RA rheumatoid arthritis (RA), have an increased risk of cardtiovascular disease (CVD), particulary ischemic heart disease (IHD). This…
Abstract Number: 555 • 2017 ACR/ARHP Annual Meeting
The Corrected QT(QTc) Interval Is Associated with Myocardial Fibrosis in Primary Sjögren Syndrome, Assessed By a Cardiac Magnetic Resonance Approach: A Prospective Pilot Study at a Single Center
Atsuma Nishiwaki¹, Hitomi Kobayashi¹, Isamu Yokoe², Yosuke Nagasawa³, Kaita Sugiyama³, Natsumi Ikumi⁴, Takamasa Nozaki³, Noboru Kitamura⁵ and Masami Takei⁵, ¹Hematology and Rheumatology, Nihon University School of Medicine, Tokyo, Japan, ²Rheumatology, Kyoundo Hospital, Sasaki Institute, Tokyo, Japan, ³Nihon University School of Medicine, Tokyo, Japan, ⁴St. Vincent's University Hospital, Department of Rheumatology, Dublin, Ireland, ⁵Division of Hematology and Rheumatology, Nihon University School of Medicine, Tokyo, Japan
Background/Purpose: Congenital heart block in the fetus and neonate, which can cause acquired QT prolongation, may be associated with maternal anti-SS-A/anti-SS-B autoantibodies. However, there are…
Abstract Number: 1239 • 2017 ACR/ARHP Annual Meeting
Web Based Educational Intervention to Improve Cardiovascular Disease Knowledge Among RA Patients
Meenakshi Jolly¹, Aman Kugasia², Carlos Cordova³, Joshlean Fair³, Eleftheria Steinig⁴, Rasa Kazkauskaite⁵, Lisa Walt⁶, Mondira Sengupta⁷ and Joel A. Block², ¹Rush, Chicago, IL, ²Division of Rheumatology, Rush University Medical Center, Chicago, IL, ³Rheumatology, Rush University Medical Center, Chicago, IL, ⁴Northwestern Univeristy, Chicago, IL, ⁵Rush University, chicago, IL, ⁶American Hospital Association, Chicago, IL, ⁷John H Stroger Hospital of Cook County, Chicago, IL
Background/Purpose: The major cause of mortality in patients with Rheumatoid Arthritis (RA) is cardiovascular disease (CVD). However traditionally, very few RA patients receive screening and…
Abstract Number: 1789 • 2017 ACR/ARHP Annual Meeting
Improved Survival with Transplantation in Granulomatosis with Polyangiitis in the United States: Data from the US Renal Data System
Zachary S. Wallace¹, Rachel Wallwork², Leo Lu³, John H. Stone⁴, Yuqing Zhang⁵ and Hyon K. Choi⁶, ¹Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ²Department of Medicine, Massachusetts General Hospital, Boston, MA, ³Allergy, Immunology, and Rheumatology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁴Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, ⁵Department of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁶Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA
Improved Survival with Transplantation in Granulomatosis with Polyangiitis in the United States: Data from the US Renal Data SystemBackground/Purpose: Granulomatosis with polyangiitis (GPA) is a…
Abstract Number: 2525 • 2017 ACR/ARHP Annual Meeting
Influence of Cardiovascular Comorbidity on Achieving Therapeutic Goals: A Comparative Study between Recent-Onset Psoriatic Arthritis and Established Disease
Rubén Queiro¹ and Juan D. Cañete², ¹Rheumatology Department. Hospital Universitario Central de Asturias, Oviedo, Spain, ²Rheumatology Department, Arthritis Unit, Rheumatology Dpt, Hospital Clinic of Barcelona, Barcelona, Spain
Background/Purpose: Some cardiovascular risk factors (CVRF) have been associated with a lower probability of achieving a good therapeutic response in PsA1. However, the reason for…
Abstract Number: 657 • 2017 ACR/ARHP Annual Meeting
Dyslipidemia Management Is Insufficient in Psoriatic Arthritis Despite Increased Cardiovascular Morbidity and Mortality
Richard Koch¹, JEAN BERNARD RUIDAVETS Sr.², Yannick Degboe³, Alain Cantagrel³, Adeline Ruyssen-Witrand⁴, JEAN FERRIERES⁵ and Arnaud Constantin³, ¹Department of Rheumatology, Purpan Hospital, Toulouse III University, Toulouse, France, TOULOUSE, France, ²DEPARTMENT OF EPIDEMIOLOGY, URM 1027 INSERM, TOULOUSE UNIVERSITY HOSPITAL, TOULOUSE, France, ³Department of Rheumatology, Purpan Hospital, Toulouse III University, Toulouse, France, Toulouse, France, ⁴Rheumatology, Purpan Hospital, Toulouse III University, Toulouse, France, ⁵DEPARTMENT OF CARDIOLOGY, URM 1027 INSERM, TOULOUSE UNIVERSITY HOSPITAL, TOULOUSE, France
Background/Purpose: Psoriatic arthritis (PsA) is associated with increased cardiovascular (CV) morbidity and mortality. Assessing individual CV risk and achieving the recommended LDL-cholesterol (LDL-C) target could…
Abstract Number: 1265 • 2017 ACR/ARHP Annual Meeting
Impaired Cardiac Function in Juvenile Mixed Connective Tissue Disease Compared with Controls
Birgit Nomeland Witczak¹, Siri Opsahl Hetlevik², Zoltan Barth^1,3, Thomas Schwartz^4,5, Berit Flatø^2,6, Vibke Lilleby^2,6 and Ivar Sjaastad^1,6,7, ¹Institute for Experimental Medical Research, Oslo University Hospital, Oslo, Norway, Oslo, Norway, ²Department of Rheumatology, Oslo University Hospital, Rikshospitalet, Oslo, Norway, Oslo, Norway, ³Department of Pathophysiology and Gerontology, Medical School, University of Pècs, Pècs, Hungary, Pècs, Hungary, ⁴Oslo University Hospital and University of Oslo, Institute for Experimental Medical Research, Oslo, Norway, ⁵Department of Infectious Diseases, Oslo University Hospital, Oslo, Norway, Oslo, Norway, ⁶Institute for Clinical Medicine, University of Oslo, Oslo, Norway, Oslo, Norway, ⁷Department of Cardiology, Oslo University Hospital, Oslo, Norway, Oslo, Norway
Background/Purpose: Juvenile MCTD (JMCTD) is a heterogenic autoimmune disease, with SLE-, SSc- and PM/DM and RA like manifestations. Cardiac involvement is known in juvenile SLE,…
Abstract Number: 1812 • 2017 ACR/ARHP Annual Meeting
Preeclampsia and Incident Cardiovascular Disease in SLE Pregnancy
Julia F Simard¹, Marios Rossides², Elizabeth V. Arkema³, Elisabet Svenungsson⁴, Anna-Karin Wikstrom⁵, Murray Mittleman⁶ and Jane E. Salmon⁷, ¹Division of Epidemiology, Health Research and Policy Department, Stanford School of Medicine, Stanford, CA, ²Medicine Solna, Clinical Epidemiology Unit, Karolinska Institutet, Stockholm, Sweden, ³Clinical Epidemiology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, ⁴Department of Medicine Solna, Rheumatology Unit, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, Stockholm, Sweden, ⁵Clinical Epidemiology Unit, Department of Medicine, Karolinska Institute, Stockholm, Sweden, ⁶Epidemiology, Harvard T. H. Chan School of Public Health, Boston, MA, ⁷Medicine/Rheumatology, Hospital of Special Surgery, New York, NY
Background/Purpose: Pre-pregnancy cardiovascular health has been associated with preeclampsia during pregnancy, as well as future cardiovascular disease (CVD). Preeclampsia is related to endothelial dysfunction, hypertension,…
Abstract Number: 2527 • 2017 ACR/ARHP Annual Meeting
Increased Prevalence of Subclinical Atherosclerosis in Moderate-Severe Plaque Psoriasis Patients
Nuria Vegas-Revenga¹, José Luis Martín-Varillas¹, Susana Armesto², Marcos A González- López³, Virginia Portilla², Patricia Fuentevilla¹, Javier Rueda-Gotor², Carlos Fernández-Díaz¹, Lucia C. Domínguez-Casas¹, Belén Atienza-Mateo¹, Jose L. Hernández⁴, Ricardo Blanco¹, Miguel Angel González-Gay¹ and Alfonso Corrales¹, ¹Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ²Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ³Dermatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ⁴Internal Medicine, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain
Background/Purpose: Surrogate markers of subclinical atherosclerosis and cardiovascular (CV) mortality such as carotid plaques (CP), arterial stiffness (AS) and carotid intima-media thickness (c-IMT), have been…
Abstract Number: 686 • 2017 ACR/ARHP Annual Meeting
Endothelial Dysfunction in Systemic Lupus Erythematosus Patients without Cardiovascular events and Risk Factors: Correlation with Microvascular Alterations and angiogenic t Cells
Ilaria Cavazzana¹, Mara Taraborelli², Silvia Piantoni³, Ivano Bonadei⁴, Edoardo Sciatti⁵, Micaela Fredi⁶, Marco Metra⁴, Angela Tincani⁷, Franco Franceschini¹ and Enrico Vizzardi⁴, ¹Rheumatology and Clinical Immunology, Spedali Civili of Brescia, Brescia, Italy, ²Internal Medicine; Ospedale Mellini, Chiari (Brescia), Italy, ³Rheumatology and Clinical Immunology Unit, Spedali Civili, University of Brescia, Brescia, Italy, ⁴Cardiology Unit, Spedali Civili, University of Brescia, Brescia, Italy, ⁵Cardiology Unit, Spedali Civili, University of Brescia, Brsecia, Italy, ⁶Department of Rheumatology and Clinical Immunology, Rheumatology and Clinical Immunology, Rheumatology and Clinical Immunology, Spedali Civili of Brescia, Brescia, Italy, ⁷Rheumatology and Clinical Immunology, Spedali Civili and University of Brescia, Brescia, Italy
Background/Purpose: early identification of subclinical cardiovascular disease (CVD) in systemic lupus erythematosus (SLE) patients is mandatory to reduce morbidity and mortality. Endothelial dysfunction (ED) is…
Abstract Number: 1266 • 2017 ACR/ARHP Annual Meeting
Geographic Variation in Use of Echocardiography at Diagnosis and Detection of Acute Cardiac Disease in Youth with Systemic Lupus Erythematosus
Joyce C. Chang¹, Andrea M. Knight², Laura M. Mercer-Rosa³, Rui Xiao⁴ and Pamela F. Weiss⁵, ¹Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ²Division of Rheumatology, Center for Pediatric Clinical Effectiveness & PolicyLab, Children's Hospital of Philadelphia, Philadelphia, PA, ³Division of Cardiology, Children's Hospital of Philadelphia, Philadelphia, PA, ⁴Department of Biostatistics and Epidemiology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ⁵Division of Rheumatology, Center for Pediatric Clincial Effectiveness, Children's Hospital of Philadelphia, Philadelphia, PA
Background/Purpose: Child-onset systemic lupus erythematosus (SLE) is a chronic autoimmune condition with a high risk of organ damage. There are no guidelines on the use…
Abstract Number: 1864 • 2017 ACR/ARHP Annual Meeting
Longitudinal Changes in Serum Uric Acid Levels and Associated Risk of Cardiometabolic Events and Renal Insufficiency in Gout Patients
Rishi J. Desai¹, Jessica Franklin², Julia Spoendlin², Goodarz Danaei³, Daniel H. Solomon⁴ and Seoyoung C. Kim⁵, ¹PharmacoEpidemiology & PharmacoEconomics, Brigham & Women's Hospital, Boston, MA, ²Brigham & Women's Hospital, Boston, MA, ³Harvard School of Public Health, Boston, MA, ⁴Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁵Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Gout patients have an increased risk of type 2 diabetes mellitus (T2DM), cardiovascular disease (CVD), and chronic kidney disease (CKD); however, it is not…
Abstract Number: 2546 • 2017 ACR/ARHP Annual Meeting
Secukinumab Decreases Arterial Wall Inflammation in Patients with Peripheral Spondyloarthritis
Leonieke van Mens¹, Simone Verweij², Arno van Kuijk³, Erik Stroes² and Dominique Baeten¹, ¹AMC, Amsterdam Immunology and Rheumatology Center, Amsterdam, Netherlands, ²Vascular Medicine, Academisch Medisch Centrum, Amsterdam, Netherlands, ³Reade, Amsterdam Immunology and Rheumatology Center, Amsterdam, Netherlands
Background/Purpose: Patients with spondyloarthritis (SpA), a chronic inflammatory disease, have an increased cardiovascular risk, which is partly due to increased inflammatory activity in the arterial…
Abstract Number: 743 • 2017 ACR/ARHP Annual Meeting
Impact of Detect on Right Heart Catheterization Referral and Results; Data from a Prospective, Unselected, Systemic Sclerosis Cohort
Anna-Maria Hoffmann-Vold¹, Håvard Fretheim², Anders Heiervang Tennøe², Oyvind Midtvedt², Torhild Garen², Einar Gude², Arne K Andreassen² and Øyvind Molberg², ¹Division of Rheumatology, Oslo University Hospital, Oslo, Norway, ²Oslo University Hospital, Oslo, Norway
Background/Purpose: The DETECT calculator has been freely available as a tool for earlier detection and diagnosis of pulmonary arterial hypertension (PAH) in systemic sclerosis (SSc)…
Abstract Number: 1267 • 2017 ACR/ARHP Annual Meeting
Blood Pressure Control over Time in Childhood-Onset Systemic Lupus Erythematous
Pinar Ozge Avar Aydin¹, Jian Shan², Hermine I. Brunner¹ and Mark Mitsnefes³, ¹Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Peking Union Medical College Hospital, Peking, China, Peking, China, ³Cincinnati Children’s Hospital Medical Center, Cincinnati, OH
Background/Purpose: Cardiovascular disease (CVD) is the leading cause of increased long-term morbidity and mortality in systemic lupus erythematosus (SLE). As an important modifiable risk factor…

« Previous Page
1
…
8
9
10
11
12
…
38
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.